Tafenoquine Cures All Patients in 60 Degrees Pharma's Babesiosis Trial
SXTP sits 75% above its 52-week low of $1.36.
Summary
60 Degrees Pharmaceuticals announced highly positive results from its expanded use clinical trial for relapsing babesiosis, reporting that all three enrolled immunosuppressed patients were cured after treatment with tafenoquine combined with other therapies. This outcome, combined with previous Yale study data, suggests a near 100% cure rate across seven patients for this serious, emerging tick-borne illness which currently lacks an FDA-approved treatment. For a micro-cap biotech, these results are materially significant, potentially opening a new and substantial market opportunity for tafenoquine (ARAKODA®), which is already approved for malaria prophylaxis. Investors will be watching for further regulatory engagement, potential larger clinical trials, and the company's efforts to influence treatment guidelines for babesiosis.
At the time of this announcement, SXTP was trading at $2.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $1.36 to $17.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.